Objective: To explore the roles of estrogen receptor-related receptor (ERR) alpha and estrogen receptor alpha in endometrial carcinoma and their clinical values.
Methods: Thirty-five cases of endometrial carcinoma were examined by immunohistochemistry. Clinicopathologic features including FIGO stage, histological grade, myometrial invasion and nodal metastasis were reviewed.
Results: The expression rate of ERalpha in patients with FIGO stage I endometrial carcinoma was more than that in stage II-IV(P = 0.005). The expression rate of ERRalpha in endometrial carcinoma patients at FIGO stage I was lower than that at stages II-IV(P = 0.007). The percentage of patients at FIGO stageI or with G1-2 or myometrial invasion < 1/2 in ERalpha (+) and ERRalpha (-) groups was higher than that in ERalpha (-) and ERRalpha (+) groups(P = 0.000, P = 0.031 and P = 0.022).
Conclusion: ERalpha may be a biomarker of good prognosis while ERRalpha may serve as a biomarker of poor prognosis in endometrial carcinoma. The combinative measure of ERalpha and ERRalpha may improve the prognostic value.